You are here
- 10/27/2014 - 18:24
Abiraterone and prednisone in men with CRPC prior to docetaxel earlier showed improved progression-free survival but follow up was too short to meet the co-primary endpoint of the COU-AA302 study: overall survival.
Cabozantinib fails to significantly prolong survival in men with metastatic Castration-Resistant Prostate Cancer09/24/2014 - 09:50
Cabozantinib (XL184) is an oral tyrosine kinase inhibitor with activity against MET and vascular endothelial growth factor receptor 2. Although other VEGFR-targeting agents have failed in prostate cancer, expectations amongst oncologists were high that cabozantinib that also targets c-Met, critical in bone metastasis, would be a winning horse in metastatic castrate-resistant prostate cancer.